Jelena Kunovac, MD: The Difficulty of Treating Schizophrenia

Article

Antipsychotic discontinuation remains a major hurdle for effective schizophrenia treatment.

Schizophrenia remains one of the more difficult disorders to treat, largely because of a wide array of symptoms and a high rate of antipsychotic discontinuations for patients.

Because the disease presents itself with both negative and positive symptoms, finding a “one-size fits all” medication has proven difficult, if not impossible.

While it has proven easier to find a medication that can treat the positive symptoms, such as hallucinations and delusions, developing a medication that also can treat the social isolation and paranoia is much less efficient.

This combination, as well as the likelihood of a schizophrenia patient to alienate family and loved ones, increases the rate of discontinuation substantially.

The antipsychotics commonly prescribed for schizophrenia also may include various side effects, including weight gain and headaches.

In an interview with HCPLive®, Jelena Kunovac, MD, MS, Chief Medical Officer, Altea Research, explained why it has been so difficult to develop new treatments for the disease.

“Unfortunately, we’ve yet to come up with a treatment for schizophrenia that has no side effects,” Kunovac said. “And whoever does may very well be the top contender for the Nobel Prize.”

Related Videos
Rebecca A. Andrews, MD: Issues and Steps to Improve MDD Performance Measures
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data
Daniel Karlin, MD: FDA Grants Breakthrough Designation to MM120 for Anxiety
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Leesha Ellis-Cox: Steps to Closing the Bipolar Disorder Diagnosis Gap for Blacks
Daniel Greer, PharmD: Reduction in Rehospitalizations with Antipsychotic Injections for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.